

## Murine Norovirus

Noroviruses are nonenveloped RNA viruses with high environmental resistance and belong to the family *Caliciviridae*, genus *Norovirus*. They were first identified after an outbreak of acute gastroenteritis at a school in Norwalk/Ohio (USA) in 1968 and cause about 90% of nonbacterial epidemic gastroenteritis in humans. Noroviruses found in animals include bovine, porcine and murine noroviruses. Noroviruses are not known to cross species.

The first norovirus to infect mice was described in 2003 (1). Experimental inoculation studies with this murine norovirus (MNV-1) show that duration of infection and disease manifestation vary depending on the mouse strain (1-3). In immunocompetent strains, MNV-1 infection is variable in length (e.g.  $\geq$  7-14 days in 129S6 mice,  $\geq$  5 weeks in Hsd:ICR mice) and does not induce clinical signs. Infection is associated with mild histopathological alterations in the small intestine (increase in inflammatory cells) and spleen (red pulp hypertrophy and white pulp activation) of 129S6 mice. In certain immunodeficient strains, however, infection can cause lethal systemic disease (encephalitis, vasculitis, meningitis, hepatitis and pneumonia in interferon- $\alpha\beta\gamma$  receptor $^{-/-}$  and Stat1 $^{-/-}$  mice) or persist without symptoms ( $\geq$  90 days in Rag1 $^{-/-}$  und Rag2 $^{-/-}$  mice). These findings indicate that components of the innate immune system are critical for resistance to MNV-1 induced disease. Consistent with this hypothesis, Wobus et al. (4) demonstrated that MNV-1 replicates in macrophages and dendritic cells. Meanwhile, many additional strains of MNV with diverse biological properties were isolated (5, 6). An analysis of 26 MNV isolates revealed 15 distinct MNV strains that comprise a single genogroup and serotype (6). Experimental inoculation studies show that several MNV strains are able to persist in various tissues (small intestine, caecum, mesenteric lymph node, spleen) of immunocompetent (C57BL/6J, Hsd:ICR, Jcl:ICR) and immunodeficient (C.B-17-Prkdc<sup>scid</sup>) mice with viral shedding in faeces for the duration of at least 35-60 days (5-7). MNV is transmitted via the faecal-oral route and is efficiently transferred to sentinel mice by soiled bedding (8, 9).

Embryo transfer (8) and hysterectomy (7) are most likely effective means of eliminating MNV from mouse colonies. Since 1- to 3-day-old pups are resistant to infection, elimination of MNV may also be achieved by transferring neonates from infected dams to uninfected foster dams ("cross fostering") (10, 11). This transfer should ideally be performed within 24 hours after birth.

MNV infection can be detected directly by RT-PCR on faecal pellets or tissue specimens (see above) and indirectly by serology (1-3, 5-15). Detection is facilitated by high stability of MNV RNA in faeces (at least 2 weeks at room temperature) (9) and by broad serological cross-reactivity among different strains of MNV (5, 6). Health surveillance data from North America (2, 15) and Western Europe (12-14) demonstrate a high prevalence of MNV infections in laboratory mice. In the hitherto largest survey (15), 32.4% of 44,876 mouse serum samples examined had antibodies against MNV.

The impact of MNV on animal experiments remains to be evaluated. Recent studies show that MNV is immunomodulatory and may alter disease phenotypes in mouse models of inflammatory bowel disease (16-18).

### References:

1. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HW. 2003. STAT1-dependent innate immunity to a Norwalk-like virus. *Science* 299:1575-8.
2. Hsu CC, Wobus CE, Steffen EK, Riley LK, Livingston RS. 2005. Development of a microsphere-based serologic multiplexed fluorescent immunoassay and a reverse transcriptase PCR assay to detect murine norovirus 1 infection in mice. *Clin Diagn Lab Immunol* 12:1145-51.

3. Mumphrey SM, Changotra H, Moore TN, Heimann-Nichols ER, Wobus CE, Reilly MJ, Moghadamfalahi M, Shukla D, Karst SM. 2007. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. *J Virol* 81:3251-63.
4. Wobus CE, Karst SM, Thackray LB, Chang K-O, Sosnovtsev SV, Belliot G, Krug A, Mackenzie JM, Green KY, Virgin HW. 2004. Replication of *Norovirus* in cell culture reveals a tropism for dendritic cells and macrophages. *PLoS Biol* 2:2076-84.
5. Hsu CC, Riley LK, Wills HM, Livingston RS. 2006. Persistent infection with and serologic cross-reactivity of three novel murine noroviruses. *Comp Med* 56:247-51.
6. Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, Henderson KS, Kelley ST, Virgin HW. 2007. Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. *J Virol* 81:10460-73.
7. Goto K, Hayashimoto N, Yasuda M, Ishida T, Kameda S, Takakura A, Itoh T. 2009. Molecular detection of murine norovirus from experimentally and spontaneously infected mice. *Exp Anim* 58:135-40.
8. Perdue KA, Green KY, Copeland M, Barron E, Mandel M, Faucette LJ, Williams EM, Sosnovtsev SV, Elkins WR, Ward JM. 2007. Naturally occurring murine norovirus infection in a large research institution. *J Am Assoc Lab Anim Sci* 46:39-46.
9. Manuel CA, Hsu CC, Riley LK, Livingston RS. 2008. Soiled-bedding sentinel detection of murine norovirus 4. *J Am Assoc Lab Anim Sci* 47:31-6.
10. Artwohl JE, Purcell JE, Fortman JD. 2008. The use of cross-foster rederivation to eliminate murine norovirus, *Helicobacter* spp., and murine hepatitis virus from a mouse colony. *J Am Assoc Lab Anim Sci* 47:19-24.
11. Compton SR. 2008. Prevention of murine norovirus infection in neonatal mice by fostering. *J Am Assoc Lab Anim Sci* 47:25-30.
12. Müller B, Klemm U, Mas Marques A, Schreier E. 2007. Genetic diversity and recombination of murine noroviruses in immunocompromised mice. *Arch Virol* 152:1709-19.
13. Mähler M, Köhl W. 2009. A serological survey to evaluate contemporary prevalence of viral agents and *Mycoplasma pulmonis* in laboratory mice and rats in western Europe. *Lab Anim. (NY)* 38(5):161-5.
14. Mahabir E, Bensch S, Brielmeier M, Schmidt J. 2009. Prevalence of murine norovirus in a breeding and experimental mouse facility. Proceedings of the Tenth FELASA Symposium and the XIV ICLAS General Assembly & Conference, p. 88-90.
15. Pritchett-Coming KR, Cosentino J, Clifford CB. 2009. Contemporary prevalence of infectious agents in laboratory mice and rats. *Lab Anim* 43:165-73.
16. Chase Lencioni K, Seamons A, Treuting PM, Maggio-Price L, Brabb T. 2008. Murine norovirus: an intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease. *Comp Med* 58:522-33.
17. Achard M, Mähler M, Neumann D, Zschemisch N-H, Janus LM, Köhl W, Smoczek A, Hedrich HJ, Bleich A. 2009. Impact of murine norovirus on a mouse model of IBD (Abstract). *Gastroenterology* 136:A706.
18. Cadwell K, Patel KK, Maloney NS, Liu T-C, Ng ACY, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW. 2010. Virus-plus-susceptibility gene interaction determines Crohn's disease gene *Atg16L1* phenotypes in intestine. *Cell* 141:1135-45.

Date: 07/08/2010